120 related articles for article (PubMed ID: 8642867)
1. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'.
Planken EV; Dijkstra NH; Willemze R; Kluin-Nelemans JC
Leukemia; 1996 Mar; 10(3):488-93. PubMed ID: 8642867
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of purified malignant B cells induced by PMA or by activated normal T cells.
van Kooten C; Rensink I; Aarden L; van Oers R
Leukemia; 1993 Oct; 7(10):1576-84. PubMed ID: 8105156
[TBL] [Abstract][Full Text] [Related]
3. IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro.
Brass U; Tretter T; Schneller F; Schuler M; Huber C; Peschel C
J Interferon Cytokine Res; 1999 Apr; 19(4):335-43. PubMed ID: 10334384
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
[TBL] [Abstract][Full Text] [Related]
5. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation.
Pellat-Deceunynck C; Amiot M; Robillard N; Wijdenes J; Bataille R
Cancer Res; 1996 Apr; 56(8):1909-16. PubMed ID: 8620513
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest.
Santos-Argumedo L; Gordon J; Heath AW; Howard M
Cell Immunol; 1994 Jul; 156(2):272-85. PubMed ID: 7517793
[TBL] [Abstract][Full Text] [Related]
7. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Kedar R; Sabag O; Licthenstein M; Lorberboum-Galski H
Cancer; 2012 Dec; 118(24):6089-104. PubMed ID: 22692727
[TBL] [Abstract][Full Text] [Related]
9. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
10. In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand.
Buske C; Twiling A; Gogowski G; Schreiber K; Feuring-Buske M; Wulf GG; Hiddemann W; Wörmann B
Leukemia; 1997 Nov; 11(11):1862-7. PubMed ID: 9369419
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
12. Selective response of CD5+ B cell malignancies to activation of the CD72 antigen.
Planken EV; Van de Velde H; Falkenburg JH; Thielemans K; Willemze R; Kluin-Nelemans JC
Clin Immunol Immunopathol; 1998 Apr; 87(1):42-9. PubMed ID: 9576009
[TBL] [Abstract][Full Text] [Related]
13. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
[TBL] [Abstract][Full Text] [Related]
14. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C
Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
16. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
Matutes E; Owusu-Ankomah K; Morilla R; Garcia Marco J; Houlihan A; Que TH; Catovsky D
Leukemia; 1994 Oct; 8(10):1640-5. PubMed ID: 7523797
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.
Cabezudo E; Carrara P; Morilla R; Matutes E
Haematologica; 1999 May; 84(5):413-8. PubMed ID: 10329919
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.
Takeuchi T; Barcos MP; Seon BK
Cancer Res; 1991 Jun; 51(11):2985-93. PubMed ID: 1709587
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated changes identified by quantitative flow cytometry. III. B-cell gating in CD37/kappa/lambda clonality test.
Peters RE; Janossy G; Ivory K; al-Ismail S; Mercolino T
Leukemia; 1994 Nov; 8(11):1864-70. PubMed ID: 7967732
[TBL] [Abstract][Full Text] [Related]
20. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation.
Nelson BP; Variakojis D; Peterson LC
Mod Pathol; 2002 Nov; 15(11):1111-20. PubMed ID: 12429788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
